This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Shijiazhuang Pharma. Group Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Chao Liu: Innovator in Pharmaceutical Complexes
Introduction: Chao Liu is a notable inventor based in Hebei, China. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on inclusion complexes. His research focuses on enhancing the solubility and therapeutic effects of butylphthalide, a compound with potential health benefits.
Latest Patents: Chao Liu holds a patent for "Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof." This invention relates to the complexation of butylphthalide with cyclodextrin or its derivatives, specifically hydroxypropyl-β-cyclodextrin. The aim is to improve the water solubility of butylphthalide, facilitating the development of various clinical formulations such as infusions, injections, and oral medications. He has 1 patent to his name.
Career Highlights: Throughout his career, Chao Liu has worked with prominent companies in the pharmaceutical industry. He has been associated with Shijiazhuang Pharmaceutical Group and Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. His work in these organizations has contributed to advancements in drug formulation and delivery.
Collaborations: Chao Liu has collaborated with esteemed colleagues, including Zhan-qi Niu and Kai Zhao. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical sector.
Conclusion: Chao Liu's contributions to the field of pharmaceuticals through his innovative patent on butylphthalide inclusion complexes highlight his role as a significant inventor. His work continues to impact the development of effective therapeutic formulations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile